Loading...
XTAI
1734
Market cap194mUSD
Jul 15, Last price  
31.50TWD
1D
0.48%
1Q
1.78%
Jan 2017
40.88%
IPO
236.54%
Name

Sinphar Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
18.73
P/S
1.81
EPS
1.68
Div Yield, %
3.17%
Shrs. gr., 5y
1.76%
Rev. gr., 5y
5.64%
Revenues
3.15b
+6.33%
1,813,468,0001,822,648,0001,840,266,0002,086,627,0002,577,907,0002,642,145,0002,187,401,0002,133,511,0002,134,163,0002,215,837,0002,394,589,0002,388,452,0002,433,516,0002,856,651,0002,962,934,0003,150,628,000
Net income
305m
-18.78%
131,034,000110,930,00072,229,000121,304,000300,691,000163,393,00013,952,00016,545,00036,726,0008,785,000-147,922,000-172,559,000-204,959,000164,174,000375,170,000304,705,000
CFO
594m
+100.26%
309,944,000261,494,000225,583,000164,449,000297,092,000148,580,000280,533,00087,184,000219,871,00079,502,000-79,486,000146,392,000135,544,000425,298,000296,370,000593,512,000
Dividend
Sep 04, 20241 TWD/sh

Profile

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products. The company also offers shampoo, body wash, tonic water, lotions, moisturizers, sunscreen lotions, and serums; and pharmaceutical packaging products, such as eye drop bottles, dry canisters, tablet bottles, and various medical grade plastic containers. In addition, it provides plant extracts and functional foods; and OEM services, such as product design, manufacturing, etc. to manufacturers. The company was founded in 1977 and is headquartered in Yilan City, Taiwan.
IPO date
Oct 17, 2000
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,150,628
6.33%
2,962,934
3.72%
2,856,651
17.39%
Cost of revenue
2,856,622
2,672,515
2,658,849
Unusual Expense (Income)
NOPBT
294,006
290,419
197,802
NOPBT Margin
9.33%
9.80%
6.92%
Operating Taxes
21,883
(51,068)
80,872
Tax Rate
7.44%
40.89%
NOPAT
272,123
341,487
116,930
Net income
304,705
-18.78%
375,170
128.52%
164,174
-180.10%
Dividends
(167,722)
(167,722)
(33,544)
Dividend yield
2.93%
2.94%
0.65%
Proceeds from repurchase of equity
30,043
BB yield
-0.53%
Debt
Debt current
721,523
450,878
497,899
Long-term debt
1,181,205
1,494,142
1,415,618
Deferred revenue
Other long-term liabilities
148,064
154,371
106,814
Net debt
772,416
841,659
651,266
Cash flow
Cash from operating activities
593,512
296,370
425,298
CAPEX
(240,437)
(295,510)
(153,445)
Cash from investing activities
(391,078)
(334,563)
(124,238)
Cash from financing activities
(209,083)
(106,842)
(263,325)
FCF
265,849
38,163
145,606
Balance
Cash
1,178,037
1,081,149
1,244,216
Long term investments
(47,725)
22,212
18,035
Excess cash
972,781
955,214
1,119,418
Stockholders' equity
2,425,669
2,975,424
2,478,127
Invested Capital
4,624,188
4,542,051
4,072,354
ROIC
5.94%
7.93%
2.82%
ROCE
5.25%
5.28%
3.81%
EV
Common stock shares outstanding
183,173
181,473
168,013
Price
31.20
-0.76%
31.44
2.44%
30.69
14.69%
Market cap
5,715,000
0.17%
5,705,526
10.65%
5,156,319
14.89%
EV
6,770,392
6,846,721
6,094,203
EBITDA
551,376
533,943
464,516
EV/EBITDA
12.28
12.82
13.12
Interest
36,771
33,711
27,813
Interest/NOPBT
12.51%
11.61%
14.06%